Mizuho raised the firm’s price target on Envista (NVST) to $19 from $18 and keeps an Underperform rating on the shares. Envista continued its trend of modest market share gains in Q3 from what the firm believe is a better-positioned product portfolio than broad dental peers, says the analyst, who raised the firm’s 2025 and 2026 EPS estimates to reflect the market share gains.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVST:
- Envista Holdings’ Earnings Call Highlights Strong Growth
- Envista price target raised to $27 from $25 at Baird
- Envista Holdings: Strong Q3 Performance and Upward Guidance, Yet Valuation Concerns Justify Hold Rating
- Envista Holdings: Positive Growth Trends and Margin Improvements Drive Buy Rating
- Envista Holdings Reports Strong Q3 2025 Results